Nitrogen Attached Directly Or Indirectly To The Purine Ring System By Nonionic Bonding Patents (Class 544/276)
-
Patent number: 7307166Abstract: The invention relates to certain oxypurine nucleosides, congeners of such oxypurine nucleosides, and acyl derivatives thereof, and compositions which contain at least one of these compounds. The invention also relates to methods of treating or preventing hematopoietic disorders and modifying hematopoiesis, and treating or preventing inflammatory diseases and bacterial infections by administering a compound or composition of the present invention to an animal.Type: GrantFiled: June 5, 1995Date of Patent: December 11, 2007Assignee: Wellstat Therapeutics CorporationInventors: Reid W. von Borstel, Michael K. Bamat, Bradley M. Hiltbrand, James C. Butler, Shyam Shirali
-
Patent number: 7303773Abstract: A process for enhancing theanine extraction from plant material through a series of extraction, adsorption and filtration steps. More specifically, disclosed is a process for isolating theanine from a plant material, which includes the steps of: a) contacting the plant material with a solvent to obtain an extract comprising theanine; b) contacting the theanine extract with an adsorbent to obtain a theanine-containing eluate; and c) subjecting the theanine eluate to a filtration step to obtain a theanine-rich extract.Type: GrantFiled: October 21, 2003Date of Patent: December 4, 2007Assignee: The Procter & Gamble CompanyInventors: Athula Ekanayake, Jianjun Justin Li
-
Publication number: 20070270440Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.Type: ApplicationFiled: May 18, 2007Publication date: November 22, 2007Applicant: WyethInventors: Derek Cecil Cole, Magda Asselin, Joseph Raymond Stock, Jin-In Kim
-
Patent number: 7273864Abstract: The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage, using compounds of the following formula: wherein R4 is a functional group including, for example, C1-4alkyl, C3-8cycloalkyl, hydroxyl-C1-4alkyl, aryl-C0-3alkyl, substituted with 0-2 R4a groups, and heterocyclo-C0-2alkyl, optionally substituted with C1-4alkyl; R5 is hydrogen and R6 is a functional group including, for example, halogen, C1-4alkyl, —C(O)—C1-4alkyl, —SO2—N(R2b R2b), halo—C1-4alkyl, —O-aryl and —N(R7 R8), or when R5 and R6 are on adjacent ring atoms they are optionally taken together to form —O—(CH2)1-2—O—; and all pharmaceutically acceptable salts and hydrates thereof.Type: GrantFiled: October 15, 2003Date of Patent: September 25, 2007Assignee: The Scripps Research InstituteInventors: Xu Wu, Sheng Ding, Nathanael S. Gray
-
Patent number: 7259159Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.Type: GrantFiled: July 23, 2001Date of Patent: August 21, 2007Assignees: Sanofi-Aventis Deutschland GmbH, Genentech Inc.Inventors: Anuschirwan Peyman, David Will, Thomas R Gadek, Robert McDowell, Jean Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle
-
Patent number: 7256196Abstract: The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,8,9-substituted purines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: GrantFiled: December 7, 2004Date of Patent: August 14, 2007Assignee: The Procter & Gamble CompanyInventors: Mark Sabat, Michael Philip Clark, Todd Andrew Brugel, Adam Golebiowski, John Charles Van Rens, Biswanath De
-
Patent number: 7253154Abstract: The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.Type: GrantFiled: November 14, 2002Date of Patent: August 7, 2007Assignee: Nippon Chemiphar Co., Ltd.Inventors: Shinichi Yoshida, Atsushi Tendo, Kunio Kobayashi, Nobutaka Mochiduki, Tomio Yamakawa, Yoriko Shinohara
-
Patent number: 7241890Abstract: Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.Type: GrantFiled: October 30, 2002Date of Patent: July 10, 2007Assignee: Conforma Therapeutics CorporationInventors: Srinivas Rao Kasibhatla, Kevin Hong, Lin Zhang, Marco Antonio Biamonte, Marcus F. Boehm, Jiandong Shi, Junhua Fan
-
Patent number: 7238700Abstract: Disclosed are novel A2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R1 is optionally substituted alkyl or a group —Y-Z, in which Y is a covalent bond or optionally substituted alkylene, and Z is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkenyl or optionally substituted alkynyl, with the proviso that when Y is a covalent bond Z cannot be alkenyl or alkynyl; and X is oxygen, sulfur, or NH—, or a pharmaceutically acceptable salt, ester, or prodrug thereof. The compounds are particularly useful for treating asthma and diabetic retinopathy.Type: GrantFiled: April 30, 2004Date of Patent: July 3, 2007Assignee: CV Therapeutics, Inc.Inventors: Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki, Dengming Xiao
-
Patent number: 7217702Abstract: Selective antagonists of A2A adenosine receptors like those of formula I are provided, wherein Y forms a ring. The novel A2A blockers are useful for the treatment of Parkinsons disease and other diseases.Type: GrantFiled: April 4, 2005Date of Patent: May 15, 2007Assignee: Adenosine Therapeutics, LLCInventors: Anthony Beauglehole, Jayson M. Rieger, Robert D. Thompson
-
Patent number: 7211668Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is sulfur or oxygen; J is nitrogen or C—R?; R1, R? is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy or a functional group having one of following general formulae: wherein A1, A2, A3, A4, A5, is independently selected from H, halogen such as F, Cl, Br or I, CF3, alkyl, preferably C1–C4 alkyl, nitro, nitrile, alkoxy, preferably C1–C4 alkoxy, halogenated (such as F, Cl, Br and I) alkyl, preferably halogenated C1–C4 alkyl, halogenated (such as F, Cl, Br and I) alkoxy, preferably halogenated C1–C4 alkoxy, phenyl, and halogenated (such as F, Cl, Br and I phenyl; R2 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucType: GrantFiled: April 6, 2004Date of Patent: May 1, 2007Assignee: Panagene, Inc.Inventors: Sung Kee Kim, Hyunil Lee, Jong Chan Lim, Sung Hee Lee
-
Patent number: 7199127Abstract: Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; R1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3? are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocarbonyl, whereas R3 and R3? do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.Type: GrantFiled: October 24, 2003Date of Patent: April 3, 2007Assignees: United States of America, Represented by the Secretary, Department of Health and Human Services, Ewha Womans UniversityInventors: Lak Shin Jeong, Kenneth A. Jacobson, Hyung Ryong Moon, Hea Ok Kim
-
Patent number: 7196093Abstract: 1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, multiple sclerosis or diabetes.Type: GrantFiled: April 9, 2003Date of Patent: March 27, 2007Assignee: General AtomicsInventor: Chong-Sheng Yuan
-
Patent number: 7189849Abstract: Novel processes towards the synthesis of the antiviral valomaciclovir stearate in which an esterified guanine acetal is reduced to the corresponding alcohol, reacted with an activated amino acid and N-deprotected. The esterified guanine acetal is prepared from a 9-guanine derivative bearing an acyclic hydroxymethylbutylacetal. The processes are amendable to one-pot reactions.Type: GrantFiled: May 18, 2005Date of Patent: March 13, 2007Assignee: Medivir ABInventors: M. Robert Leanna, Michael Rasmussen, Steven M. Hannick, Jien-Heh J. Tien, Kirill A. Lukin, Zhenping Tian, Sou-Jen Chang, Cynthia B. Curty, Bikshandarkoil A. Narayanan, John Bellettini, Bhadra Shelat, Tiffany Spitz
-
Patent number: 7189730Abstract: Disclosed are novel A2A adenosine receptor antagonists of the formula: wherein: R1 is optionally substituted aryl or optionally substituted heteroaryl; R2 is optionally substituted lower alkyl or optionally substituted cycloalkyl; R3 is hydrogen, halogen, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl; X is —O—, —S—, or —NH—; and Y is optionally substituted alkylene; and the pharmaceutically acceptable salts thereof; which are useful for treating various disease states, for example cardiovascular disorders, including tissue damage due to ischemia, CNS diseases, including Parkinson's disease, depression, and the like.Type: GrantFiled: December 18, 2002Date of Patent: March 13, 2007Assignee: CV Therapeutics, Inc.Inventor: Gloria Cristalli
-
Patent number: 7183268Abstract: Compounds which are active against viruses have the following Formulas: wherein B is 2-aminopurine-9-yl, which may be unsubstituted or substituted in the 6 position with NHR1, OR2, or SR3; R1 is selected from the group consisting of alkyl, alkenyl, alkynyl, and C4-18 cycloalkyl, any of which may be optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl; R2 is selected from the group consisting of C2-18 alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl, and aryl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl.Type: GrantFiled: September 15, 2004Date of Patent: February 27, 2007Assignees: Wayne State University, The Regents of the University of MichiganInventors: Jiri Zemlicka, John C. Drach, Xinchao Chen
-
Patent number: 7179896Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is nitrogen or C—R?; J is sulfur or oxygen; R?, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.Type: GrantFiled: July 15, 2005Date of Patent: February 20, 2007Assignee: Panagene, Inc.Inventors: Sung Kee Kim, Hyunil Lee, Jong Chan Lim, Hoon Choi, Jae Hoon Jeon, Sang Youl Ahn, Sung Hee Lee, Won Jun Yoon
-
Patent number: 7176312Abstract: General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls has been demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via palladium catalyzed cross-coupling reactions.Type: GrantFiled: October 12, 2002Date of Patent: February 13, 2007Assignees: The Scripps Research Institute, IRM LLCInventors: Sheng Ding, Qiang Ding, Nathanael S. Gray
-
Patent number: 7157465Abstract: This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.Type: GrantFiled: April 15, 2002Date of Patent: January 2, 2007Assignee: Dainippon Simitomo Pharma Co., Ltd.Inventors: Yoshiaki Isobe, Haruhisa Ogita, Masanori Tobe, Haruo Takaku, Tetsuhiro Ogino, Ayumu Kurimoto, Hajime Kawakami
-
Patent number: 7145006Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is nitrogen or C—R?; J is sulfur or oxygen; R?, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.Type: GrantFiled: July 15, 2005Date of Patent: December 5, 2006Assignee: Panagene, Inc.Inventors: Sung Kee Kim, Hyunil Lee, Jong Chan Lim, Hoon Choi, Jae Hoon Jeon, Sang Youl Ahn, Sung Hee Lee, Won Jun Yoon
-
Patent number: 7138401Abstract: 2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.Type: GrantFiled: September 20, 2004Date of Patent: November 21, 2006Assignee: Conforma Therapeutics CorporationInventors: Srinivas Rao Kasibhatla, Kevin D. Hong, Marcus F. Boehm, Marco A. Biamonte, Lin Zhang
-
Patent number: 7122669Abstract: Derivatives of purine having anti-proliferative properties and in particular, derivatives of purine endowed with an inhibitory effect vis-a-vis cycline-dependent kinase proteins i.e. abbreviated to “cdk”.Type: GrantFiled: May 18, 2000Date of Patent: October 17, 2006Assignee: Hoechst Marion RousselInventor: Jean-Luc Haesslein
-
Patent number: 7105666Abstract: The present invention provides a method for producing 2-, 6-, 8- and 9-substituted purine compounds from 4,6-dihalo-5-nitro-2-alkyl-pyrimidine compounds in solution or by solid phase techniques. The present process provides for the sequential introduction of amine substituents at the 4- and 6-positions, displacement of an alkylsulfony group at the 2-position of the pyrimidine, reduction of the nitro group and formation of the imidazole portion of the purine compound. Furthermore, the methods of the present invention are ideally suited to the preparation of a library of purine compounds.Type: GrantFiled: June 27, 2003Date of Patent: September 12, 2006Assignee: Roche Palo Alto LLCInventors: Lars G.J. Hammarström, Nancy Elisabth Krauss, Sharada Shenvi Labadie, David Bernard Smith, Francisco Xavier Talamas
-
Patent number: 7087589Abstract: The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloakyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2 receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1 receptors), cardiac ischemia (through A1, A3 receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2A receptors).Type: GrantFiled: January 12, 2001Date of Patent: August 8, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Victor E. Marquez
-
Patent number: 7078524Abstract: The present invention relates to an industrial useful process for the synthesis of antiviral compound, ganciclovir which comprises dissolving a mixture containing N-7 and N-9 isomers of structural formulae, II and III, respectively: in a solvent or a mixture of solvents; separating the N-7 and N-9 isomers; and hydrolizing the N-9 isomer to obtain ganciclovir.Type: GrantFiled: November 22, 2002Date of Patent: July 18, 2006Assignee: Ranbaxy Laboratories LimitedInventors: Jayachandra Suresh Babu, Purna Chandra Ray, Yatendra Kumar, Chandra Has Khanduri
-
Patent number: 7074929Abstract: This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y.Type: GrantFiled: November 10, 2003Date of Patent: July 11, 2006Assignees: Neurogen Corp., Pfizer, Inc.Inventors: Raymond F. Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
-
Patent number: 7034152Abstract: Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.Type: GrantFiled: December 11, 2003Date of Patent: April 25, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Yadagiri R. Pendri, Chung-Pin H. Chen, Sunil S. Patel, Jeffrey M. Evans, Jing Liang, David R. Kronenthal, Gerald L. Powers, Siva Josyula Prasad, Jeffrey T. Bien, Zhongping Shi, Ramesh N. Patel, Amit Banerjee, Yeung Yu Chan, Sushil K. Rijhwani, Ambarish K. Singh, Shaopeng Wang, Milan Stojanovic, David J. Kucera, Richard P. Polniaszek, Charles Lewis, John Thottathil, Dhileepkumar Krishnamurty, Maotang X. Zhou, Purushotham Vemishetti
-
Patent number: 7022851Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein R1, R2, R3, R4, R5 is independently H, halogen, C1–C4 alkyl, nitro, nitrile, C1–C4 alkoxy, halogenated C1–C4 alkyl, or halogenated C1–C4 alkoxy, wherein at least one of R1, R3, and R5 is nitro; R6 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases.Type: GrantFiled: January 24, 2003Date of Patent: April 4, 2006Assignee: Panagene, Inc.Inventors: Sung Kee Kim, Hyunil Lee, Jong Chan Lim, Hoon Choi, Jae Hoon Jeon, Sang Youl Ahn, Sung Hee Lee
-
Patent number: 7005430Abstract: A condensed purine derivative represented by Formula (I): wherein X—Y-Z represents R1N—C?O or N?C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y-Z represents R1aN—C?O and R2 represents a substituted lowerType: GrantFiled: December 22, 2000Date of Patent: February 28, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kimihisa Ueno, Akira Ogawa, Yoshihisa Ohta, Yuji Nomoto, Kotaro Takasaki, Hideaki Kusaka, Hiroshi Yano, Chiharu Nakagawa, Satoshi Nakanishi
-
Patent number: 6998484Abstract: The present invention relates to a new method for the synthesis of purine LNA (Locked Nucleic Acid) analogues which provides a higher overall yield. The method comprising a regioselective 9-N purine glycosylation reaction followed by a one-pot nucleophilic aromatic substitution reaction of the 6-substituent in the purine ring and simultaneous nucleophile-induced intramolecular ring closure of the C-branched carbohydrate to form novel purine LNA analogues. The novel strategy is illustrated by the synthesis of the novel compound (1S,3R,4R,7S)-7-benzyloxy-1-methanesulfonylmethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane which is easily converted into (1S,3R,4R,7S)-7-hydroxy-1-hydroxymethyl-3-((2-N-isobutyrylguanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane after isobutyryl protection of the 2-amino purine group and subsequent substitution of 1-methanesulfonyl with benzoate, debenzoylation and debenzylation.Type: GrantFiled: October 4, 2001Date of Patent: February 14, 2006Assignee: Santaris Pharma A/SInventors: Troels Koch, Flemming Ressig Jensen
-
Patent number: 6992188Abstract: Corticotropin-releasing factor (CRF) antagonists having the formula wherein the dashed lines, A, B, D E, F, Z, G, R3, and R5 having the definitions set forth in the specification pharmaceutical compositions containing them.Type: GrantFiled: December 6, 1996Date of Patent: January 31, 2006Assignee: Pfizer, Inc.Inventor: Yuhpyng L. Chen
-
Patent number: 6969720Abstract: The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present invention constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound. Examples of the compounds of the present invention are represented by the following chemical structures: wherein: X=N; V=NH; O; S; or CH2; A=CH2; (CH2)2; (CH2)3; OCH2CH2; or CHCH3; and Y, R1, R2, R3, R4, and n1 are defined herein.Type: GrantFiled: September 11, 2001Date of Patent: November 29, 2005Assignee: AMR Technology, Inc.Inventor: Michael Peter Trova
-
Patent number: 6969766Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is nitrogen or C—R?; J is sulfur or oxygen; R?, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.Type: GrantFiled: April 25, 2003Date of Patent: November 29, 2005Assignee: Panagene, Inc.Inventors: Sung Kee Kim, Hyunil Lee, Jong Chan Lim, Hoon Choi, Jae Hoon Jeon, Sang Youl Ahn, Sung Hee Lee, Won Jun Yoon
-
Patent number: 6958344Abstract: The invention provides certain heterocyclic compounds, processes, and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).Type: GrantFiled: February 7, 2001Date of Patent: October 25, 2005Assignee: AstraZeneca ABInventors: Roger Bonnert, Peter Cage, Fraser Hunt, Iain Walters, Paul Willis
-
Patent number: 6949644Abstract: The invention provides general methods for preparing 2,9-, 2,6,9-, O6-aryl- and O6-alkyl-substituted purines in a combinatorial and traceless fashion. The methods involve, in some embodiments, Mitsunobu alkylation of 2-fluoro-6-phenylsulfenylpurine at N9 with alcohols in solution, followed by C2-capture of the purine core with a resin-bound amine and subsequent oxidation and displacement of the C6 sulfonyl group with amines and anilines. In one aspect, the present invention provides a method of preparing a 2,6,9-substituded purine compounds of Formula I: the method comprising: a) oxidizing a resin-bound compound of Formula II: to provide a resin-bound compound of Formula III: b) reacting the compound of Formula III with an amine of Formula IV NR3R4??IV, to provide a resin-bound compound of Formula V c) cleaving the resin-bound compound of Formula V from the resin to provide the substituted purine compounds of Formula I.Type: GrantFiled: October 12, 2002Date of Patent: September 27, 2005Assignees: IRM LLC, The Scripps Research InstituteInventors: Sheng Ding, Qiang Ding, Nathanael S. Gray, Peter G. Schultz
-
Patent number: 6949559Abstract: The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present invention constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound. Examples of the compounds of the present invention are represented by the following chemical structures: with X, Y, D, Q, V, A, R1, R2, R3, R4, and n1 defined herein.Type: GrantFiled: October 7, 2003Date of Patent: September 27, 2005Assignee: AMR Technology, Inc.Inventor: Michael Peter Trova
-
Patent number: 6939965Abstract: Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include reacting a 5-O-protected-oxymethyl-1,3-oxathiolane with a silylated nucleoside in the presence of (Cl)3Ti(isopropoxide). Using the processes described herein, the compounds can be provided as isolated enantiomers.Type: GrantFiled: February 11, 2003Date of Patent: September 6, 2005Assignees: Gilead Sciences, Inc., Emory UniversityInventors: George R. Painter, Dennis C. Liotta, Merrick R. Almond, Darryl G. Cleary, José D. Soria, Marcos Sznaidman
-
Patent number: 6926763Abstract: The invention features compounds of the formula: or a pharmaceutically acceptable salt thereof, wherein A is CR2 and B is N; wherein n is 0-3; wherein R1 is (CH2)m—{(G)o—(CH2)p}q—L, in which G is CH2, CH?CH, C?C, CO, O, S, or NR5, where R5 is H or C1-6 alkyl, CHR6, where R6 is OH or C1-6 alkyl, CH(CR7R8), where each of R7 and R8 is, independently, H, halo, or C1-6 alkyl, OCO, CONR9, NR10CO, where each of R9 and R10 is, independently, H or C1-6 alkyl, SO2NH, or NHSO2; in which m is 1-4, o is 0-4, p is 0-4, and q is 0-4. The compounds disclosed herein have potent anti-microbial, e.g., both Gram-positive and Gram-negative anti-bacterial properties. The compounds inhibit DNA polymerase IIIC and DNA polymerase IIIE enzymes and thus act therapeutically by inhibiting the growth of a broad array of bacteria. The compounds can be administered to prevent or to treat Gram-positive or Gram-negative bacterial infections, e.g., in eukaryotic cell cultures, animals, or humans.Type: GrantFiled: February 10, 2003Date of Patent: August 9, 2005Assignee: GLSynthesis, Inc.Inventors: George E. Wright, Wei-Chu Xu, Neal C. Brown
-
Patent number: 6924271Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.Type: GrantFiled: November 27, 2002Date of Patent: August 2, 2005Assignee: Anadys Pharmaceuticals, Inc.Inventors: Devron R. Averett, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden
-
Patent number: 6919332Abstract: The present invention relates to N-substituted-heteroaryloxy-aryloxy-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.Type: GrantFiled: April 28, 2003Date of Patent: July 19, 2005Assignee: Pfizer Inc.Inventors: Mark C. Noe, Lilli Ann Wolf-Gouveia
-
Patent number: 6906076Abstract: The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.Type: GrantFiled: September 12, 2003Date of Patent: June 14, 2005Assignee: Cytokine Pharmasciences, Inc.Inventors: Michael I. Bukrinsky, Anthony Cerami, Peter Ulrich, Bradley Berger
-
Patent number: 6906190Abstract: A polymerase inhibitor has first moiety coupled to a second moiety via an optional linker in which the first moiety binds to an initiation nucleotide binding site of a polymerase and forms at least two hydrogen bonds with an RNA template strand that is associated with the polymerase, and in which the second moiety comprised a compound that binds to a site proximal to the nucleotide binding site of the polymerase and thereby increases the affinity of the polymerase inhibitor to the polymerase.Type: GrantFiled: December 27, 2002Date of Patent: June 14, 2005Assignee: Ribapharm Inc.Inventors: Nanhua Yao, Haoyun An, Todd Appleby, Shahul Nilar, Yili Ding, Zhi Hong
-
Patent number: 6894045Abstract: Compounds provided herein are novel substituted tetrahydropurinones of Formula (I): wherein R3 is aryl substituted with 0-5 XAr or heteroaryl substituted with 0-4 XhAr. Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.Type: GrantFiled: July 10, 2002Date of Patent: May 17, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Richard A. Hartz
-
Patent number: 6855821Abstract: Disclosed are novel processes for preparing 1,3-dioxolane nucleosides of general formula I and II: wherein B is a purine or pyrimidine base or an analog or derivative thereof. The invention also provides intermediates for use in the preparation of these compounds.Type: GrantFiled: August 6, 2003Date of Patent: February 15, 2005Assignee: Pharmasset, Ltd.Inventors: Jinfa Du, Kyoichi A. Watanabe
-
Patent number: 6849660Abstract: Provided are antibacterial compounds having Formula I: In such compositions, X is O or S; Y is CH2; n is 0 or 1. One of R1 and R1? is —C(O)NR5R5?, —C(O)—Q—NR5R5?, —CH2NR5R5? or —S(O)2NR5R5? and the other is H or R3. One of R2 and R2? is —NHC(O)R6 or —NHS(O)2R6 and the other is H or R4. Q is an amino acid or peptide. R3 is H, halogen, —NR5R5? or —NHC(O)R6; and R4 is selected from the group consisting of H, halogen, hydroxyl, amino, carboxyl, alkyl, alkenyl and alkynyl. R5 is selected from the group consisting of H, alkyl, alkenyl or alkynyl optionally substituted with halogen, OH, amino, amidinyl, guanidinyl, urea, alkyl, carboxyl, oxo, carboxamide; R5? is H or R5 and R5? together form a 5-16 member heterocycle optionally substituted with halogen, OH, amino, alkyl, carboxyl, carbonyl or carboxamide.Type: GrantFiled: August 1, 2000Date of Patent: February 1, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Elizabeth Jefferson, Eric Swayze
-
Patent number: 6849737Abstract: The present invention relates to protected valacyclovir, N-tert-butoxycarbonyl-L-valine 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy] ethyl ester, and a method of making it. The present invention further relates to a method of making valacyclovir including the steps of coupling an amine protected valine selected from N-t-butoxycarbonyl valine and N-formyl valine with acyclovir using a coupling agent to form a protected valacyclovir, and deprotecting the protected valacyclovir to form valacyclovir or a pharmaceutically acceptable salt thereof. The present invention further relates to valacyclovir in pure form, a method of making pure valacyclovir, and to compositions containing pure valacyclovir.Type: GrantFiled: November 13, 2002Date of Patent: February 1, 2005Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Marina Yu Etinger, Lev M. Yudovich, Michael Yuzefovich, Gennady A. Nisnevich, Ben Zion Dolitzky, Boris Pertsikov, Boris Tishin, Dina Blasberger
-
Patent number: 6849736Abstract: Provided are novel polymorphs and pseudopolymorphs of valacyclovir hydrochloride and pharmaceutical compositions containing these. Also provided are methods for making the novel polymorphs and pseudopolymorphs, which include valacyclovir hydrochloride monohydrate and valacyclovir hydrochloride dihydrate.Type: GrantFiled: September 6, 2002Date of Patent: February 1, 2005Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Shlomit Wizel, Judith Aronhime, Valerie Niddam-Hildesheim, Ben-Zion Dolitzky, Marina Yu Etinger, Michael Yuzefovich, Gennady A. Nisnevich, Boris Pertsikov, Boris Tishin, Dina Blasberger
-
Patent number: 6846927Abstract: A process for the preparation of a compound of formula (A) wherein: X is hydrogen, hydroxy, chloro, C1-6 alkoxy or phenyl C1-6 alkoxy; and Ra and Rb are hydrogen, or acyl or phosphate derivatives thereof, which process comprises: (i) the preparation of a compound of formula (I) whereiff R1 is C1-6 alkyl, or phenyl C1-6 alkyl in which the phenyl group is optionally substituted; R2 is hydrogen hydroxy, chlorine, C1-6 alkoxy, phenyl C1-6 alkoxy or amino; and R3 is halogen, C1-6 alkylthio, C1-6 alkylsulphonyl, azido, an amino group or a protected amino group, which preparation comprises the reaction of a compound of formula (II), wherein R2 and R3 are as defined for formula (I) with a compound of formula (V) wherein L is a leaving group and R1 is as defined for formula (I), to give a compound of formula (VI), and thereafter converting the intermediate compound of formula (VI) to a compound of formula (I) via decarboxylation, and, as necessary or desired, interconverting variables R1, R2 and R3 to further values oType: GrantFiled: March 11, 1999Date of Patent: January 25, 2005Assignee: Novartis International Pharmaceutical Ltd.Inventor: John Robert Mansfield Dales
-
Patent number: 6838559Abstract: Purine phosphodiesterase 7 (PDE 7) inhibitors of the following formulas wherein R1, Z, Y and J are described herein, and analogs thereof are provided which are useful in treated T-cell mediated diseases. R2 is defined by the following (a) heteroaryl, or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; (b) aryl substituted with one to three groups T1, T2, T3 provided that at least one of T1, T2, T3 is other than H; or (c) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3.Type: GrantFiled: June 17, 2002Date of Patent: January 4, 2005Assignee: Bristol-Myers Squibb Co.Inventors: Wayne Vaccaro, Jacques Y. Roberge, Katerina Leftheris, William J. Pitts, Joseph Barbosa
-
Patent number: RE39056Abstract: Compounds of structural Formula (I) and pharmacologically acceptable salts and esters thereof possess 5?-reductase inhibitory activity. These compounds inhibit 5?-reductase type 1 and type 2. The compounds of structural Formula I are useful in the systemic, including oral, and parenteral, including topical, treatment and prevention of hyperandrogenic conditions including prostatic carcinoma, benign prostatic hyperplasia, acne vulgaris, seborrhea, androgenic alopecia (also called androgenetic alopecia) which includes male- and female-pattern baldness, female hirsutism, and prostatitis. A class of compounds of the present invention are also potent antiandrogens. The present invention also relates to novel compositions containing such compounds, methods of their use and methods of their manufacture.Type: GrantFiled: September 11, 1996Date of Patent: April 4, 2006Assignee: Merck & Co, Inc.Inventors: Raman K. Bakshi, Soumya P. Sahoo, Richard L. Tolman